Alectinib(Alecensa)

Alectinib is a tyrosine kinase inhibitor that exerts its effects by selectively inhibiting the activities of anaplastic lymphoma kinase (ALK) and RET.

150mg*112capsules

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Alectinib Drug News

FDA Approves Alecensa (alectinib) for ALK-Positive Non-Small Cell Lung Cancer

FDA Approval AnnouncementDecember 11, 2015 -- The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced ···【Read More】
Update: 04 Mar,2026Source: Haiou HealthViews: 71
FDA Approves Alecensa (alectinib) as First-Line Treatment for ALK-Positive Metastatic Non-Small Cell

FDA Approval AnnouncementSouth San Francisco, CA -- November 6, 2017 - Genentech, a member of the Roche Group, today announced that the U.S. Food and ···【Read More】
Update: 04 Mar,2026Source: Haiou HealthViews: 71
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Earl

FDA Approval AnnouncementSouth San Francisco, CA -- April 18, 2024 -- Genentech, a member of the Roche Group, announced today that the U.S. Food and D···【Read More】
Update: 04 Mar,2026Source: Haiou HealthViews: 72